



09-0285 JC02 Rec'd PCT/PTO 31 AUG 2005 PCT

Express Mail No.: EV531695805US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Muller et al.

Confirmation No.: 9094

Application No.: 10/535,004

Group Art Unit: To Be Assigned

Filed: May 11, 2005

Examiner: To Be Assigned

For: METHODS OF USING AND
COMPOSITIONS COMPRISING (+)-
3-(3,4-DIMETHOXY-PHENYL)-3-(1-
OXO-1,3-DIHYDRO-ISOINDOL-2-
YL)-PROPIONAMIDE

Attorney Docket No.: 9516-058-999

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references **A01 to A84, B01 to B08, and C01 to C10** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant."

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), because this Information Disclosure Statement is being filed before the first Office Action, it is estimated that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date August 31, 2005

Y. Insogna

Anthony M. Insogna

by Yeats and Moon
Reg. No. 52,042
35,203

(Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosures

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.

9516-058-999

APPLICATION NO.

10/535,004

APPLICANT

Muller et al.

FILING DATE

May 11, 2005

GROUP

To Be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	09/642,557		Bennett et al. (10624-046-999)			08-18-00
	A02	10/316,673		Muller et al. (9516-194-999)			12-11-02
	A03	10/748,085		Man et al. (9516-084-999)			12-29-03
	A04	10/900,270		Muller et al. (9516-323-999)			07-28-04
	A05	10/900,332		Muller et al. (9516-324-999)			07-28-04
	A06	60/454,155		Muller et al. (9516-098-888)			03-12-03
	A07	60/454,149		Man et al. (9516-099-888)			03-12-03
	A08	60/452,460		Muller et al. (9516-088-888)			03-05-03
	A09	60/438,450		Muller et al. (9516-065-888)			01-07-03
	A10	60/438,448		Muller et al. (9516-064-888)			01-07-03
	A11	60/436,975		Muller et al. (9516-084-888)			12-30-02
	A12	60/427,379		Muller et al. (9516-058-888)			11-18-02
	A13	2005/0014727	01-20-05	Muller et al.			
	A14	2004/0167199	08-26-04	Muller et al.			
	A15	2004/0167174	08-26-04	Man et al.			
	A16	2004/0147588	07-29-04	Man et al.			
	A17	2004-0127536	07-01-04	Bhagwat et al.			
	A18	2004/006096	01-08-04	Muller et al.			
	A19	2004-0029832	02-12-04	Zeldis			
	A20	2004/0019106	01-29-04	Muller et al.			
	A21	2003-0220330	11-27-03	Satoh et al.			
	A22	2003/0187052	10-02-03	Muller et al.			
	A23	2003-0073732	04-17-03	Sakata et al.			
	A24	2003/0045726	03-06-03	Muller			
	A25	2002-0103229	08-01-02	Bhagwat et al.			
	A26	3,536,809	10-27-70	Applezweig			
	A27	3,598,123	08-10-71	Zaffaroni			
	A28	3,845,770	11-05-74	Theeuwes et al.			
	A29	3,916,899	11-04-75	Theeuwes et al.			
	A30	4,008,719	02-22-77	Theeuwes et al.			
	A31	5,059,595	10-22-91	La Grazie			
	A32	5,073,543	12-17-91	Marshall et al.			
	A33	5,120,548	06-09-92	McClelland et al.			

	A34	5,354,556	10-11-94	Sparks et al.			
	A35	5,463,063	10-31-95	Muller			
	A36	5,591,767	01-07-97	Mohr et al.			
	A37	5,605,914	02-25-97	Muller			
	A38	5,632,984	05-27-97	Wong et al.			
	A39	5,635,517	06-03-97	Muller et al.			
	A40	5,639,476	06-17-97	Oshlack et al.			
	A41	5,658,940	08-19-97	Muller et al.			
	A42	5,674,533	10-07-97	Santus et al.			
	A43	5,698,579	12-16-97	Muller			
	A44	5,703,098	12-30-97	Muller			
	A45	5,728,844	03-17-98	Muller			
	A46	5,728,845	03-17-98	Muller			
	A47	5,733,566	03-31-98	Lewis			
	A48	5,736,570	04-07-98	Muller			
	A49	5,770,589	06-23-98	Billson			
	A50	5,798,368	08-25-98	Muller et al.			
	A51	5,801,195	09-01-98	Muller et al.			
	A52	5,877,200	03-02-99	Muller			
	A53	5,929,117	07-27-99	Muller et al.			
	A54	5,955,476	09-21-99	Muller et al.			
	A55	5,968,945	10-19-99	Muller et al.			
	A56	6,001,368	12-14-99	Jenks			
	A57	6,011,050	01-04-00	Muller et al.			
	A58	6,015,803	01-18-00	Wirostko			
	A59	6,020,358	01-04-00	Muller et al.			
	A60	6,046,221	04-04-00	Muller et al.			
	A61	6,075,041	06-13-00	Muller			
	A62	6,130,226	10-10-00	Muller et al.			
	A63	6,180,644	01-30-01	Muller et al.			
	A64	6,200,987	03-13-01	Muller			
	A65	6,214,857	04-10-01	Muller et al.			
	A66	6,218,369	04-17-01	Bombardelli et al.			
	A67	6,225,348	05-01-01	Paulson			
	A68	6,262,101	07-17-01	Muller et al.			
	A69	6,281,230	08-28-01	Muller et al.			
	A70	6,284,780	09-04-01	Muller et al.			
	A71	6,326,388	12-04-01	Man et al.			
	A72	6,380,239	04-30-02	Muller et al.			
	A73	6,395,754	05-28-02	Muller et al.			
	A74	6,403,613	06-11-02	Man et al.			
	A75	6,429,221	08-06-02	Muller et al.			

	A76	6,458,810	10-01-02	Muller et al.			
	A77	6,479,554	11-12-02	Muller et al.			
	A78	6,518,281	02-11-03	Muller et al.			
	A79	6,656,964	12-02-03	Muller et al.			
	A80	6,667,316	12-23-04	Man et al.			
	A81	6,699,899	03-02-04	Man et al.			
	A82	6,844,359	01-18-05	Muller			
	A83	6,897,231	05-24-05	Bhagwat et al.			
	A84	6,911,464	06-28-05	Man et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO 95/01348	01-12-95	PCT				
	B02	WO 97/08143	03-06-97	PCT				
	B03	WO 97/23457	07-03-97	PCT				
	B04	WO 99/06041	02-11-99	PCT				
	B05	WO 01/34606	05-17-01	PCT				
	B06	WO 01/45702	06-28-01	PCT				
	B07	WO 03/080048	10-02-03	PCT				
	B08	WO 03/080049	10-02-03	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Beavo et al., 1990, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors," Trends Pharmacol. Sci. 11(4):150-155
	C02	Cartensen, 1995, Drug Stability: Principles & Practice, 2 nd ed., Marcel Dekker, New York, NY pp. 379-380
	C03	Corral, L.G. et al., Ann. Rheum. Dis. 58:(Suppl I) 1107-1113 (1999)
	C04	Hidaka et al., 1976, "Human blood platelet 3': 5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase," Biochim. Biophys. Acta. 429(2):485-497
	C05	Muller et al., 1998, "Thalidomide analogs and PDE4 inhibition," Bioorg. Med. Chem. Lett. 8(19):2669-2674
	C06	Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity," J. Med. Chem. 39(17):3238-3240
	C07	Nicholson et al., 1991, "Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes," Trends. Pharmacol. Sci. 12(1):19-27
	C08	Wilens, 1972, Tables of Resolving Agents and Optical Resolutions, Eliel, ed., Univ. Notre Dame Press, Notre Dame, IN, pp. 268
	C09	Wilens et al., 1977, Tetrahedron 33:2725
	C10	Wolff, ed., 1995, Burger's Medicinal Chemistry and Drug Discovery, 5 th ed., 172-178, 949-982

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.